Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report)’s share price traded up 7% on Wednesday . The company traded as high as $1.30 and last traded at $1.30. 19,880 shares were traded during trading, an increase of 2% from the average session volume of 19,419 shares. The stock had previously closed at $1.22.
Medexus Pharmaceuticals Stock Performance
The stock’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $1.45.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
- Five stocks we like better than Medexus Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- 3 Stocks Leading the U.S. Agriculture Comeback
- How Can Investors Benefit From After-Hours Trading
- How to Use Put Debit Spreads to Profit From Falling Stocks
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
